Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Large Increase in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,448,757 shares, an increase of 74.6% from the June 30th total of 829,522 shares. Approximately 1.9% of the shares of the stock are sold short. Based on an average trading volume of 1,113,100 shares, the short-interest ratio is presently 1.3 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $4.00.

Nautilus Biotechnology Price Performance

NASDAQ:NAUT opened at $0.98 on Friday. Nautilus Biotechnology has a 12 month low of $0.62 and a 12 month high of $4.31. The firm has a market capitalization of $124.32 million, a PE ratio of -2.17 and a beta of 0.80. The business’s 50-day moving average is $2.02 and its two-hundred day moving average is $2.42.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings data on Tuesday, July 28th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.10 million.

Insider Buying and Selling

In related news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of Nautilus Biotechnology stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the completion of the sale, the insider owned 971,885 shares in the company, valued at approximately $2,283,929.75. This trade represents a 83.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 41.10% of the company’s stock.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NAUT. Garde Capital Inc. bought a new stake in shares of Nautilus Biotechnology in the 4th quarter worth $35,000. Hudson Bay Capital Management LP acquired a new position in Nautilus Biotechnology during the fourth quarter worth about $37,000. Qube Research & Technologies Ltd acquired a new position in Nautilus Biotechnology during the second quarter worth about $45,000. Virtu Financial LLC raised its position in Nautilus Biotechnology by 19.6% in the fourth quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after acquiring an additional 3,849 shares in the last quarter. Finally, XTX Topco Ltd raised its position in Nautilus Biotechnology by 86.2% in the second quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock worth $48,000 after acquiring an additional 30,641 shares in the last quarter. 50.71% of the stock is owned by institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.